Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published January 5, 2021 | Supplemental Material + Published
Journal Article Open

PACAP is a pathogen-inducible resident antimicrobial neuropeptide affording rapid and contextual molecular host defense of the brain

Abstract

Defense of the central nervous system (CNS) against infection must be accomplished without generation of potentially injurious immune cell-mediated or off-target inflammation which could impair key functions. As the CNS is an immune-privileged compartment, inducible innate defense mechanisms endogenous to the CNS likely play an essential role in this regard. Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide known to regulate neurodevelopment, emotion, and certain stress responses. While PACAP is known to interact with the immune system, its significance in direct defense of brain or other tissues is not established. Here, we show that our machine-learning classifier can screen for immune activity in neuropeptides, and correctly identified PACAP as an antimicrobial neuropeptide in agreement with previous experimental work. Furthermore, synchrotron X-ray scattering, antimicrobial assays, and mechanistic fingerprinting provided precise insights into how PACAP exerts antimicrobial activities vs. pathogens via multiple and synergistic mechanisms, including dysregulation of membrane integrity and energetics and activation of cell death pathways. Importantly, resident PACAP is selectively induced up to 50-fold in the brain in mouse models of Staphylococcus aureus or Candida albicans infection in vivo, without inducing immune cell infiltration. We show differential PACAP induction even in various tissues outside the CNS, and how these observed patterns of induction are consistent with the antimicrobial efficacy of PACAP measured in conditions simulating specific physiologic contexts of those tissues. Phylogenetic analysis of PACAP revealed close conservation of predicted antimicrobial properties spanning primitive invertebrates to modern mammals. Together, these findings substantiate our hypothesis that PACAP is an ancient neuro-endocrine-immune effector that defends the CNS against infection while minimizing potentially injurious neuroinflammation.

Additional Information

© 2020 National Academy of Sciences. Published under the PNAS license. Edited by Lawrence Steinman, Stanford University School of Medicine, Stanford, CA, and approved October 12, 2020 (received for review August 4, 2020). We thank Ling Wang and Hong-Kyu Lee, M.S. for their efforts in antimicrobial assessment of PACAP. E.Y.L. acknowledges support from the Systems and Integrative Biology Training Program (NIH T32GM008185), the Medical Scientist Training Program (NIH T32GM008042), and the Dermatology Scientist Training Program (NIH T32AR071307) at the University of California, Los Angeles. E.Y.L. also acknowledges an Early Career Research Grant from the National Psoriasis Foundation. G.C.L.W. is supported by NIH R01AI143730, NIH R01AI052453, NSF DMR1808459, and the National Psoriasis Foundation (20194384). M.R.Y. acknowledges grant support from the National Institute of Allergy and Infectious Diseases (NIAID) AI-124319 and AI-111661. K.-F.L. is supported by grants from the NIH (OD023076, MH114831, NS115183, AG054714, AG062232, and AG064049), a grant to the Salk core facility (CA014195), the Clayton Foundation and the Freeburg Foundation, and by funding from the Helen McLoraine Chair. X-ray research was conducted at Stanford Synchrotron Radiation Lightsource, SLAC National Laboratory, supported by the US Department of Energy (DOE) Office of Basic Energy Sciences under Contract DE-AC02-76SF00515. The Stanford Synchrotron Radiation Laboratory Structural Molecular Biology Program is supported by the DOE Office of Biological and Environmental Research and by the NIH, National Institute of General Medical Sciences (including P41GM103393). Data Availability: All study data are included in the paper and SI Appendix. M.R.Y. and G.C.L.W. contributed equally to this work. Author contributions: E.Y.L., A.L.F., K.-F.L., N.Y.Y., M.R.Y., and G.C.L.W. designed research; E.Y.L., L.C.C., H.W., J.L., M.H., Y.S., and J.A.W. performed research; E.Y.L., L.C.C., H.W., J.A.W., A.L.F., K.-F.L., N.Y.Y., M.R.Y., and G.C.L.W. contributed new reagents/analytic tools; E.Y.L., L.C.C., H.W., N.Y.Y., M.R.Y., and G.C.L.W. analyzed data; and E.Y.L., A.L.F., K.-F.L., N.Y.Y., M.R.Y., and G.C.L.W. wrote the paper. Competing interest statement: M.R.Y is founder and shareholder of NovaDigm Therapeutics, Inc., which pursues novel antiinfective agents and strategies; he holds patents in the area of antimicrobial peptides and related molecules. This article is a PNAS Direct Submission. We have run the SVM classifier on the PACAP metabolite identified here and found it to be antimicrobial but with a different score than the parent PACAP peptide, which is consistent with the findings of the authors. This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1917623117/-/DCSupplemental.

Attached Files

Published - e1917623117.full.pdf

Supplemental Material - pnas.1917623117.sapp.pdf

Files

e1917623117.full.pdf
Files (29.6 MB)
Name Size Download all
md5:748bf2bfb4202315c07a3715f438d408
11.8 MB Preview Download
md5:fc95e32a58ad4a23b4a7ddb4bf2162f2
17.8 MB Preview Download

Additional details

Created:
August 22, 2023
Modified:
October 23, 2023